HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
Sagimet Biosciences
Sagimet Biosciences SGMT | 0.00 |
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:
SGMT) with a Buy and maintains $29 price target.
